Bluejay Starts Evaluating Symphony IL-6 in Sepsis

 Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), today announced the initiation of a multicenter clinical study to evaluate the Symphony IL-6 test in sepsis patients (the SYMON study). The Symphony System is designed to address the need for simple, reliable, rapid, near-patient testing by providing quantitative measurements of specific biomarkers to determine the need for additional patient care and monitoring. The Symphony System was shown in published clinical studies to deliver results directly from whole blood in approximately 20 minutes.

https://www.globenewswire.com/news-release/2023/12/27/2801370/0/en/Bluejay-Diagnostics-Inc-Announces-Initiation-of-Multicenter-Clinical-Study-Evaluating-Symphony-IL-6-in-Sepsis-Patients-SYMON-Study.html